Patents for A61P 35 - Antineoplastic agents (221,099)
08/2009
08/27/2009WO2009103788A1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
08/27/2009WO2009103741A2 Use of fsh receptor ligands for diagnosis and therapy of cancer
08/27/2009WO2009103476A1 Antitumoral agents with a benzophenanthridine structure and formulations containing them
08/27/2009WO2009103199A1 A g-csf conjugate modified by water-soluble polymer
08/27/2009WO2009103157A1 Mfap4 as a marker for regulatory cells and anti-cancer cells
08/27/2009WO2009103127A1 Therapeutic peptides
08/27/2009WO2009086439A3 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
08/27/2009WO2009086438A3 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs
08/27/2009WO2009083738A3 Rna delivery vehicles
08/27/2009WO2009083009A3 Monoclonal antibodies against cd32b
08/27/2009WO2009082526A3 Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
08/27/2009WO2009076455A3 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents
08/27/2009WO2009073544A3 Methods for treating a disorder by regulating gprc6a
08/27/2009WO2009067674A3 Polymorphs of sunitinib base and processes for preparation thereof
08/27/2009WO2009051659A3 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
08/27/2009WO2009033760A3 Use of fibronectin fragment (196-203 ) as a therapeutic agent
08/27/2009WO2009033668A3 Use of a peptide as a therapeutic agent
08/27/2009WO2009033667A3 Use of a peptide as a therapeutic agent
08/27/2009WO2009026328A3 Methods of delivery of agents to leukocytes and endothelial cells
08/27/2009WO2009012280A3 Benzimidazole poly(adp-ribose)polymerase inhibitors
08/27/2009WO2008154905A3 Modifications of the histone deacetylase inhibitor suberoylanilide hydroxamic acid
08/27/2009WO2008142513A3 Phosphate-modified oligonucleotide analogs with immunostimulatory activity
08/27/2009WO2006125227A3 Fibroblast activation protein inhibitor compounds and methods
08/27/2009US20090217401 Human Monoclonal Antibodies To Programmed Death 1(PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics
08/27/2009US20090217400 Enzymes, cells and methods for site specific recombination at asymmetric sites
08/27/2009US20090217392 Anti- integrin antibodies, compositions, methods and uses
08/27/2009US20090216014 Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
08/27/2009US20090215995 isolated nucleic acids encoding B7-related polypeptides, including BSL3, which modulate cells that are important for immune and inflammatory responses, such as T-cells
08/27/2009US20090215984 Conversion of apoptotic proteins
08/27/2009US20090215908 Toll like receptor (tlr) signaling antagonist
08/27/2009US20090215904 Colchicine compositions and methods
08/27/2009US20090215874 Aptamers as agonists
08/27/2009US20090215864 Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
08/27/2009US20090215862 Micro rna
08/27/2009US20090215861 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
08/27/2009US20090215853 Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
08/27/2009US20090215852 Compositions and methods for ameliorating cachexia
08/27/2009US20090215851 Method of Preparing a Porphyrin Derivative, a Porphyrin Derivative, Use of Said Porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative
08/27/2009US20090215848 Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS)
08/27/2009US20090215835 Treatment of cancer with sorafenib
08/27/2009US20090215834 Heterocyclic inhibitors of mek and methods of use thereof
08/27/2009US20090215833 Thermodynamically stable form of a tosylate salt
08/27/2009US20090215829 Thiophene carboxamides as inhibitors of the enzyme ikk-2
08/27/2009US20090215823 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
08/27/2009US20090215805 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors
08/27/2009US20090215803 Pyrimidinones as Casein Kinase II (CK2) Modulators
08/27/2009US20090215802 Deuterium-enriched lapatinib
08/27/2009US20090215799 Heterocyclic substituted bisarylurea derivatives
08/27/2009US20090215795 Cyclic amidine derivatives
08/27/2009US20090215793 Methods for treating drug resistant cancer
08/27/2009US20090215789 Cyclic hexadepsipeptides, processes for their production and their use as pharmaceuticals
08/27/2009US20090215785 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215783 Composition for induction or inhibition of stem cell differentiation
08/27/2009US20090215775 Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
08/27/2009US20090215770 Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases
08/27/2009US20090215766 Tetracyclic inhibitors of janus kinases
08/27/2009US20090215736 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid
08/27/2009US20090215729 Microparticle compositions to modify cancer promoting cells
08/27/2009US20090215726 Phosphono-Pent-2-en-1-yl Nucleosides and Analogs
08/27/2009US20090215724 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215715 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
08/27/2009US20090215706 C-linked glucuronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
08/27/2009US20090215690 Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/ beta -catenin signaling during developmental and pathological processes; finding therapeutic anticarcinogenic agent for breast cancer
08/27/2009US20090215686 Nk1-based polypeptides and related methods
08/27/2009US20090215672 Cys-Rich, Cell Surface Glycoproteins
08/27/2009US20090215666 Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
08/27/2009US20090215175 Modulation of the poliovirus receptor function
08/27/2009US20090215089 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
08/27/2009US20090214683 Extracts of Sacred Water Lotus for the Treatment of Cancer
08/27/2009US20090214671 Personalizing Cancer Chemotherapy Based on Methylation and Germ-Line Mutational Analysis of BRCA-1
08/27/2009US20090214669 Combination anticancer therapy and pharmaceutical compositions therefore
08/27/2009US20090214634 Compositions and methods for the treatment of bladder cancer
08/27/2009US20090214632 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
08/27/2009US20090214626 Platinum Complexes For Targeted Drug Delivery
08/27/2009US20090214585 Medicament, Particularly an Anti-Cancer Medicament, for Treatment Using Immunotherapy, Particularly Autologous
08/27/2009US20090214578 Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
08/27/2009US20090214576 Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
08/27/2009US20090214571 Colon cancer related gene tom34
08/27/2009US20090214564 Anti-ephrinb2 antibodies and methods using same
08/27/2009US20090214550 Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
08/27/2009US20090214546 Novel therapeutic targets in cancer
08/27/2009US20090214541 Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
08/27/2009US20090214536 CACNA1E in Cancer Diagnosis, Detection and Treatment
08/27/2009US20090214533 Methods for converting or inducing protective immunity
08/27/2009US20090214530 MODIFIED CpG OLIGODEOXYNUCLEOTIDE WITH IMPROVED IMMUNOREGULATORY FUNCTION
08/27/2009US20090214529 Kinesin inhibitors
08/27/2009US20090214525 Novel anti-igf-ir antibodies and uses thereof
08/27/2009US20090214524 Methods and compositions for regulating cell cycle checkpoints
08/27/2009US20090214518 Methods and compositions for treating solid tumors and enhancing tumor vaccines
08/27/2009US20090214517 Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
08/27/2009US20090214505 For treating an excess of a substrate for a hyaluronidase, such as reducing scar tissue
08/27/2009US20090214494 Cancer Vaccines and Therapeutic Methods
08/27/2009US20090214492 Isolated stromal cells for use in the treatment of diseases of the central nervous system
08/27/2009US20090214479 Attenuated reovirus
08/27/2009US20090214471 Use of pegylated il-10 to treat cancer
08/27/2009US20090214465 Quinoxaline Derivatives as Antitumor Agents
08/27/2009US20090214439 Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy
08/27/2009US20090214427 Novel peptides
08/27/2009US20090214425 Tumor therapy with replication competent sindbis viral vectors
08/27/2009US20090214423 Selective targeting of tumor vasculature using radiolabelled antibody molecules